Farnesylated proteins and cell cycle progression

Journal of Cellular Biochemistry

Volumn 84, Issue SUPPL. 37, 2001, Pages 64-70

  Tamanoi, Fuyuhiko ^a,b   Kato Stankiewicz, Juran ^a   Jiang, Chen ^b   Machado, Iara ^a   Thapar, Nitika ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle; CNEP E,F; Farnesyltransferase inhibitor; Ras; Rheb; Rho

Indexed keywords

CENP F PROTEIN; CENTROMERE PROTEIN E; GUANOSINE TRIPHOSPHATASE; LONAFARNIB; PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHEB PROTEIN; RHO FACTOR; TIPIFARNIB; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CENTROMERE PROTEIN F; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPEPTIDE; NONHISTONE PROTEIN; QUINOLONE DERIVATIVE; RHEB PROTEIN, HUMAN; TRANSFERASE;

CANCER CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONFERENCE PAPER; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL CYCLE; CHROMOSOMAL PROTEINS, NON-HISTONE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; G0 PHASE; G1 PHASE; HUMANS; MICROFILAMENT PROTEINS; MONOMERIC GTP-BINDING PROTEINS; NEUROPEPTIDES; PROTEIN ISOPRENYLATION; QUINOLONES; TUMOR CELLS, CULTURED;

EID: 0035751462     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10067     Document Type: Conference Paper

References (30)

1. CENP-E as an essential component of the mitotic check-point in vitro
2. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
3. The farnesyltransferase inhibitor SCH66336 induces a G2-M or G1 pause in sensitive human tumor cell lines
4. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
5. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation
6. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells
7. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines
8. Growth inhibition of astrocytoma cells by farnesyltransferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects
9. Isotype-specific Ras-GTP levels predict the efficacy of farnesyltransferase inhibitors against human astrocytomas regardless of ras mutation status
10. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
11. A novel approach for expression cloning of small GTPases: Idenfication, tissue distribution and chromosome mapping of the human homolog of rhb
12. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
13. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
14. Loss of Rhb1, a rheb-related GTPase in fission yeast, causes growth arrest with a terminal phenotype similar to that caused by nitrogen starvation
15. Farnesyltransferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
16. Ras and Rho regulation of the cell cycle and oncogenesis
17. Prenylation of RAS and inhibitors of prenyltransferases
18. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells
19. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
20. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents
21. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
22. Protein farnesylation in mammalian cells: Effects of farnesyltransferase inhibitors on cancer cells
23. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake
24. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts
25. Characterization of Ha-ras, N-ras, Ki-Ras4B as in vitro substrates for farnesyltransferase and geranylgeranyl protein transferase type I
26. Rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein
27. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant
28. Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals
29. Protein prenylation: Molecular mechanisms and functional consequences
30. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer